---
layout: default
title: Bifonazole
parent: 僅模型預測 (L5)
nav_order: 144
evidence_level: L5
indication_count: 0
---

# Bifonazole
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Bifonazole: Antifungal Agent — Drug Repurposing Evaluation

## One-Sentence Summary

Bifonazole is an imidazole-class antifungal agent, primarily used topically for the treatment of dermatomycoses (fungal skin infections). The TxGNN model currently has **no predicted new indications** for this drug, and there are significant data gaps in mechanism of action and safety information that need to be addressed before further evaluation.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Antifungal (topical use for dermatomycoses) |
| Predicted New Indication | — (No TxGNN prediction available) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (No prediction or supporting studies) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | **Hold** |

## Why is This Prediction Reasonable?

Currently, the TxGNN model has not generated any repurposing predictions for Bifonazole. This may be due to limited representation of topical antifungal agents within the knowledge graph, or insufficient relational data linking Bifonazole to novel disease targets.

> Detailed mechanism of action data is not currently available in this evidence pack. Based on known pharmacological information, Bifonazole is an imidazole antifungal that inhibits ergosterol biosynthesis by blocking the cytochrome P450-dependent enzyme lanosterol 14α-demethylase, disrupting fungal cell membrane integrity. Its use is predominantly topical, which may limit systemic repurposing opportunities.

Without a TxGNN prediction score or candidate indication, it is not possible to assess mechanistic plausibility for any new therapeutic application at this time.

## Clinical Trial Evidence

Currently no related clinical trials registered for a new indication, as no repurposing prediction has been generated.

## Literature Evidence

Currently no related literature available for a repurposing indication, as no TxGNN prediction exists for this drug.

## Malaysia Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|------|------|------|------|
| (Not available) | (Not available) | (Not available) | (Not available) |

> Note: One registration record was retrieved from the NPRA database, but detailed licence fields (authorization number, product name, dosage form, approved indication) were not populated in the source data. Please refer to the [NPRA Product Search](https://www.npra.gov.my/) for complete product information.

## Safety Considerations

> Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in the current evidence pack. As Bifonazole is primarily a topical agent, systemic safety concerns are generally limited, but local adverse reactions (e.g., skin irritation, contact dermatitis) should be monitored.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model has not generated any repurposing predictions for Bifonazole. Combined with the absence of mechanism of action data and safety information, there is insufficient basis to advance this candidate into further evaluation at this time.

**To proceed, the following is needed:**
- **TxGNN prediction output**: Verify whether Bifonazole (DB04794) is present in the knowledge graph and, if so, re-run the prediction pipeline to confirm the absence of candidates
- **Mechanism of action (MOA) data**: Query DrugBank API to retrieve full pharmacological profile (DG002)
- **NPRA product details**: Retrieve complete registration information including approved indication text, dosage form, and authorization number
- **Package insert safety data**: Download and parse the package insert PDF from the regulatory authority to populate warnings and contraindications (DG001)
- **Reassess after data gaps are filled**: If MOA data reveals systemic targets beyond antifungal activity, re-evaluate repurposing potential
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

